Literature DB >> 18580993

[Antimicrobial susceptibility and resistance patterns of Staphylococcus aureus isolated from patients and carriers in Valdivia city, Chile].

Laura Otth R1, Myra Wilson Sch, Natalia Bustamante H, Heríberto Fernández J, Carola Otth L.   

Abstract

UNLABELLED: In vitro susceptibility of nosocomial and community acquired strains of Staphylococcus aureus must be periodically evaluated because of its continuous evolution. AIM: To know the antimicrobial susceptibility of S. aureus isolated in Valdivia, to determine the prevalence of methicillin resistance and global patterns of resistance and to compare the evolution of the susceptibility along the years.
MATERIAL AND METHODS: A total of 278 S. aureus strains were evaluated: 136 obtained from hospitalized patients, 50 belonged to outpatients and 92 to healthy carriers. Antimicrobial agents tested were: penicillin, oxacillin, vancomycin, gentamycin, ciprofloxacin, lincomycin and erythromycin.
RESULTS: Thirty three, 28 and 1.1% of strains isolated from hospitalized, outpatients and carriers, respectively, were methicillin-resistant. Six resistance patterns were found. No vancomycin resistant strain was isolated. COMMENT: It is worrisome that 2% of S. aureus strains obtained from hospitalized patients showed intermediate resistance to vancomycin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580993     DOI: /S0716-10182008000300005

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  2 in total

1.  Molecular epidemiology of hospital-onset methicillin-resistant Staphylococcus aureus infections in Southern Chile.

Authors:  G Medina; A L Egea; C Otth; L Otth; H Fernández; J L Bocco; M Wilson; C Sola
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-14       Impact factor: 3.267

2.  Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010.

Authors:  Elvira Garza-González; Michael Joseph Dowzicky
Journal:  Braz J Infect Dis       Date:  2013-01-01       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.